Vertex Pharma lifts annual revenue forecast on cystic fibrosis treatments strength
Nov 4 (Reuters) -Vertex Pharmaceuticals VRTX.O raised its annual revenue forecast on Monday after it beat third-quarter estimates on demand for its cystic fibrosis (CF) treatments.
The drugmaker now expects 2024 product revenue between $10.8 billion and $10.9 billion compared to its prior expectations of $10.65 billion to $10.85 billion.
Analysts expect annual revenue of $10.75 billion, according to estimates compiled by LSEG.
The forecast includes expectations for continued growth in its CF treatments as well as for the launch of its gene therapy, Casgevy, in approved indications and geographies, the company said.
Cystic fibrosis is a genetic disorder that affects the lungs, digestive system and other organs, which affects about 35,000 people in the United States, according to government data.
Sales of Vertex's top-selling CF drug Trikafta rose more than 13% to $2.59 billion for the quarter ended Sept. 30, beating analysts' estimate of $2.33 billion.
The company also beat third-quarter revenue estimates on Monday, helped by strong demand for its CF treatments.
Third-quarter revenue rose 12% to $2.77 billion compared to analysts' estimates of $2.72 billion.
The company's gene therapy, Casgevy, won a second U.S. approval to treat a rare blood disorder requiring regular blood transfusions in January, after it was greenlighted in December for sickle cell disease.
As of mid-October, the drugmaker has activated 45 authorized treatment centers globally for the therapy and added that an increasing number of patients across all regions have initiated cell collection.
Investors have also been closely tracking the development of the company's pain drug suzetrigine. The U.S. health regulator is expected to decide by January on Vertex's application for the non-opioid drug as a treatment for moderate-to-severe acute pain.
On adjusted basis, the company reported a profit of $4.38 per share for the reported quarter, compared to analysts' expectations of profit per share of $4.14.
Reporting by Sriparna Roy and Sneha S K in Bengaluru; Editing by Shailesh Kuber
Related Assets
Latest News
Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.
All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.
Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.
